Gilead Sciences Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
October 28, 2020 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.11, $0.16 better than the analyst estimate of $1.95. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.39 billion. Veklury (remdesivir) revenues were $873 million for the third quarter.
The recent acquisition of Immunomedics has effectively transformed Gileads growth story. Building on the foundation of our strong core business, which proved its durability once again this quarter, we have now significant opportunity to drive additional growth at an accelerated pace, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Trodelvy, an approved medicine with... More
